Natco Pharma has reached a Settlement Agreement with Onyx Therapeutics, Inc. on patent litigation related to generic versions of 10mg, 30mg and 60mg of Kyprolis. The company has partnered with Breckenridge Pharmaceutical, Inc., who will market the product in the United States.
By virtue of the settlement, Natco and Breckenridge have been granted a license permitting the launch of their generic carfilzomib product on a date that is held as confidential in 2027 or sooner depending on certain occurrences. The parties cannot make further comment as to the terms of the Settlement Agreement.
The company believes that its 10mg ANDA is sole first to file and could be eligible for 180-days marketing exclusivity for the 10mg strength under certain circumstances. Kyprolis reportedly had sales of $586 million for the year ending December 2018 in the United States. Kyprolis is a registered trademark of Onyx Therapeutics, Inc.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
